Introduction

This chapter explores strategies to tackle endocrine resistance in ER-positive metastatic breast cancer, discussing mechanisms of resistance, biomarker assessment, updated phase three data on elocestrant, and emerging treatments such as chamisestrant and imlinestrant. It also touches on the use of capiva-certib guided by the Capatello-291 study and promising agents like veptic estrant and laesophoxifene.